61 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Company Limited
10 Jul 24
Current report (foreign)
6:04am
& Structure,” “Processes & Practices,” “Management Oversight,” and “Board Culture and Dynamics” as key evaluation items, and Directors were also requested … to make self-evaluations about the “Oversight by ASC and Nomination Committee.” After incorporating the analysis and recommendations made by the third
424B2
TAK
Takeda Pharmaceutical Company Limited
28 Jun 24
Prospectus for primary offering
8:25am
of the Public Company Accounting Oversight Board (United States) by KPMG AZSA LLC, our independent registered public accounting firm.
You should read
424B5
TAK
Takeda Pharmaceutical Company Limited
27 Jun 24
Prospectus supplement for primary offering
6:01am
of the Public Company Accounting Oversight Board (United States) by KPMG AZSA LLC, our independent registered public accounting firm.
You should read
F-3ASR
EX-1.1
TAK
Takeda Pharmaceutical Company Limited
26 Jun 24
Automatic shelf registration (foreign)
8:26am
Company Accounting Oversight Board, who [(x)] audited (kansa) the annual consolidated financial statements and related notes of the Company
6-K
huz2qpmjbo7sxg
7 Jun 24
Current report (foreign)
6:07am
6-K
EX-99.1
p71eb9n0ot mq
29 May 24
Current report (foreign)
6:29am
6-K
EX-99.1
jxad3zsjcn
29 May 24
Current report (foreign)
6:24am
6-K
EX-99.1
3kabrq hq
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
yxtc ef05v
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
8l35 tstbr
6 Jul 23
Current report (foreign)
6:18am
S-8
EX-99.2
65fy zjajf3rr
28 Jun 23
Registration of securities for employees
6:35am
6-K
EX-99.1
8psoltfkgwr2h2wxczg
23 Jun 23
Current report (foreign)
6:13am
6-K
16tordhgzoz
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
v7i3te1xd
30 May 23
Current report (foreign)
6:11am
6-K
jvlt8sag2qmc
11 Jul 22
Current report (foreign)
6:05am
6-K
hgy4v0kpfufjw1pxnybr
31 May 22
Current report (foreign)
6:18am